Cite
HARVARD Citation
Stein, E. et al. (2019). Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study. Atherosclerosis. pp. e7-. [Online].